Responses
Regular and Young Investigator Award Abstracts
Novel Single-Agent Immunotherapies
1392 EVOLVE-104, a novel ULBP2-targeted T cell engager that integrates CD2 costimulation for the treatment of basal and squamous lineage tumors
Compose a Response to This Article
Other responses
No responses have been published for this article.
